Search company, investor...

Beta-Stim

Founded Year

2003

Stage

Other Investors | Alive

About Beta-Stim

Beta-Stim - Minimally invasive implantable neuro-stimulator to treat obesity and type II diabetic patients.

Headquarters Location

2 Hatohen St Caesarea Industrial Park

38900,

Missing: Beta-Stim's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Beta-Stim's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Beta-Stim

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Beta-Stim is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,898 items

Beta-Stim Patents

Beta-Stim has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/24/2008

10/7/2014

Cardiac arrhythmia, Digestive system, Electrophysiology, Electrodiagnosis, Cardiac electrophysiology

Grant

Application Date

7/24/2008

Grant Date

10/7/2014

Title

Related Topics

Cardiac arrhythmia, Digestive system, Electrophysiology, Electrodiagnosis, Cardiac electrophysiology

Status

Grant

Beta-Stim Frequently Asked Questions (FAQ)

  • When was Beta-Stim founded?

    Beta-Stim was founded in 2003.

  • What is Beta-Stim's latest funding round?

    Beta-Stim's latest funding round is Other Investors.

  • Who are the investors of Beta-Stim?

    Investors of Beta-Stim include GlenRock Israel.

  • Who are Beta-Stim's competitors?

    Competitors of Beta-Stim include NeuroLutions, Vivani Medical, Vexim, Atria Medical, AqueSys and 13 more.

Compare Beta-Stim to Competitors

NeuroLutions Logo
NeuroLutions

Neurolutions seeks to develop a platform of devices, based on Brain Computer Interface (BCI) technology, which promises to restore function to patients who are disabled as a result of neurological injury. The Company's first product, the IpsiHand, is a non-invasive EEG BCI device that will be used in a rehabilitation protocol to restore hand function to hemiparetic stroke survivors. The company was founded in 2007 and is based in Santa Cruz, California.

N
NovaLign Orthopaedics

NovaLign Orthopaedics, formerly known as OsteoLign, is developing a minimally invasive solution for long bone fractures.

S
Spinal Restoration

Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

O
Otologics

Otologics is a medical device company developing implantable hearing systems and accessories designed to enhance communication and improve the quality of life for individuals with hearing loss.

Angel Medical Systems Logo
Angel Medical Systems

Angel Medical Systems develops the AngelMed Guardian system, an implantable cardiac monitoring and alerting system that is designed to warn cardiac patients of potentially life-threatening heart conditions. The AngelMed Guardian System heart monitor is designed to track changes in the heart's electrical signal from a standard pacemaker lead, identify the signature of acute thrombotic occlusions when they occur, and then alert the patient directly to seek medical attention. The device is being studied in high risk heart patients who do not qualify for an ICD, but who have had a STEMI, NSTEMI or unstable angina in their recent past. The company was founded in 2001 and is based in Eatontown, New Jersey.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.